We are honoured to be speaking at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City next week. This premier event brings together visionaries shaping the future across multiple industries such as crypto, clean tech, and life sciences. #HCWConference.

We’re thrilled to announce that Rakovina Therapeutics will present compelling new preclinical data on our novel ATR inhibitors with CNS penetrance at the AACR-NCI-EORTC International Conference in Boston, Oct 22–26. rakovinatherapeutics.com/rakovina-thera… #AIinDrugDiscovery #Oncology #ATR

Rakovina Therapeutics featured as the trending article on Streetwise Reports – The Life Sciences Report this week. Appreciate the coverage and opportunity to share our story with the life sciences community. 🔗 thelifesciencesreport.com #biotech #lifesciences #AI #Rakovina

Rakovina Therapeutics (TSX-V: RKV, FSE: 7JO0) will present new data on novel AI-developed ATR inhibitors with CNS penetrance at the AACR-NCI-EORTC International Conference. 📅 Oct 25 | 12:30–4:00 PM ET | Poster Session C #RakovinaTherapeutics #ATRinhibitors #AACRNCIEROTC

Rakovina Therapeutics (TSX-V: RKV) presented new data at #AACRNCI showing AI-discovered ATR inhibitors with CNS penetration — a potential step forward for treating brain cancers. Learn more: 🔗 rakovinatherapeutics.com/rakovina-thera… #Biotech #AIinDrugDiscovery #CancerResearch

Rakovina will present new preclinical data at #SNO2025 from our CNS-penetrant DDR inhibitor programs: 🧠 kt-5000AI ATR inhibitors 🧠 kt-2000AI PARP1-selective inhibitors 🔗 rakovinatherapeutics.com/rakovina-thera… #BrainCancer #NeuroOncology #ATR #PARP1 $RKV

We’re heading to Honolulu for #SNO2025! 🇺🇸🧠 Presenting two posters Nov 21: • CNS-penetrant ATR (Enki™ AI) • CNS-penetrant PARP1-selective (Deep Docking™) 👉 soc-neuro-onc.org/SNO2025/SNO202…

T-3 days until we land in Honolulu for the Society for Neuro-Oncology (SNO) Annual Meeting, November 19–23. We’ll be presenting two posters on November 21. See you there! #SNO2025 #neurooncology #DrugDiscovery #DNAdamageResponse #AI #RKV

We’re heading to Honolulu for #SNO2025! 🌺🧠 On Nov 21 we present 2 AI-designed CNS cancer programs: • ATR inhibitor (Enki AI Powered) • PARP1-selective inhibitor (Deep Docking AI Powered) Read our new piece on what we’re bringing to SNO⤵️ medium.com/@mark_68062/ai…

Most cancer drugs can’t reach the brain. We’re using AI to change that. Excited to share new brain-penetrant ATR & PARP1 data at SNO 2025 on Nov 21⭐️ Daugaard Laboratory

Proud to have Prof. Mads Daugaard speaking at the 9th DDR Inhibitors Summit on how AI is shaping next-gen DDR therapeutics. Big momentum for Rakovina heading into 2026. rakovinatherapeutics.com/rakovina-thera…

Team Rakovina has landed in Honolulu for #SNO2025! We’re presenting new AI-designed brain-penetrant ATR & PARP1 data on Nov 21. Excited for an amazing week in neuro-oncology. 🔬✨

“What’s the dream scenario?” For our CSO, it’s cancer therapies that can cross the blood brain barrier and reach tumours of the brain and CNS✨ We’re unveiling the next steps toward that vision at SNO 2025 Catch our two AI-designed abstracts on Nov 21🌺🧠

Big day at #SNO2025: we’re presenting AI-designed, brain-penetrant ATR & PARP1 programs for CNS tumors today (11:30–12:45 HST)🧠

Back from #SNO2025: we shared AI-designed CNS-penetrant ATR/mTOR and PARP1 programs for brain tumors. Read our two new press releases for the full data. 🧠✨ rakovinatherapeutics.com/rakovina-thera… rakovinatherapeutics.com/rakovina-thera…

New video: Our CSO, Prof. Daugaard Laboratory explains Rakovina's AI-designed ATR+mTOR and PARP1 programs for brain tumors, and why SNO 2025 was a key milestone. Watch here 👇 riverside.fm/shared/exporte…

New article via Streetwise Reports Our #AI PARP1 & ATR+mTOR inhibitors show brain potential🧠 Powered by Variational AI & Deep Docking. #SNO2025 Read👇 streetwisereports.com/article/2025/1…

Rakovina Therapeutics was featured in InvestingNewsNetwork We use the Deep-Docking & Enki AI platforms to accelerate DDR-targeting cancer drug discovery🔬 investingnews.com/ai-insights-fo… #Biotech #AI #Oncology